Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 96 of 5804
-
Immunotherapy duo shows promise in Tough-to-Treat esophageal cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo plus PC as first-line treatment in participants with u…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Ultrasound device opens brain barrier to attack deadly tumors
Disease control OngoingPaclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB). In this trial we will implant a novel device with 9 ultrasound emitters allowing to temporarily and reversibly open…
Phase: PHASE1, PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug aims to stop breast cancer recurrence in High-Risk patients
Disease control OngoingPhase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy with 1:1 allocation to: * Arm A: Sacituzumab govitecan (days 1, 8 q3w for eight cycles); * Arm B:…
Phase: PHASE3 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Virus therapy shows promise for tough bladder cancer cases
Disease control OngoingThis is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original prot…
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Immunotherapy combo aims to outperform standard care in advanced liver cancer
Disease control CompletedThis is a prospective, randomized, open-label, parallel-group, active controlled, multi-center phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab (hereafter referred to as JS001) combined with Bevacizumab versus Sorafenib…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control OngoingThe purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung c…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill helps smokers kick the habit in major trial
Disease control CompletedThis placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
Phase: PHASE3 • Sponsor: Achieve Life Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to outperform standard therapy for advanced breast cancer
Disease control OngoingThis Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal grow…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Hope for aggressive lymphoma: targeted drug added to chemo in major trial
Disease control OngoingPhase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germ…
Phase: PHASE3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo aims to outsmart tough lung cancer
Disease control CompletedThis is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mu…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug duo aims to outperform standard lung cancer treatment
Disease control OngoingThe purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally a…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immune cell therapy takes on rare blistering skin disease
Disease control Recruiting nowA phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Engineered immune cells take aim at hard-to-treat blood cancers in kids
Disease control OngoingPatients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR…
Phase: PHASE1, PHASE2 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Massive trial tests azithromycin to prevent stillbirths and infant deaths in west africa
Prevention OngoingThe double blind randomized controlled trial will assess the efficacy of oral azithromycin administered to pregnant women and/or infants during routine care in preventing stillbirths and mortality through 6-12 months of age in Mali, West Africa, where rates of infant and under fi…
Phase: PHASE4 • Sponsor: University of Maryland, Baltimore • Aim: Prevention
Last updated Jun 27, 2026 09:02 UTC
-
Promising combo targets genetic weakness in advanced prostate cancer
Disease control OngoingThe purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Se…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Stem cell transplant shows promise for scleroderma patients
Disease control CompletedHSCT has been implemented in (inter)national treatment guidelines for diffuse cutaneous systemic sclerosis (dcSSc) and is offered in clinical care and reimbursed by national health insurance in several European countries. However, data and specific guidelines on the best timing o…
Phase: PHASE4 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New antibody therapy shows promise for Hard-to-Treat myeloma
Disease control OngoingThe purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for hard-to-treat lymphoma: drug duo takes on cancer
Disease control OngoingThe purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Immunotherapy combo shows promise in advanced lung cancer trial
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail shows promise for rare blood cancer
Disease control OngoingMyelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC